Literature DB >> 7998833

The induction of in vivo superinfection and recombination using feline immunodeficiency virus as the model.

M T Kyaw-Tanner1, W K Greene, H S Park, W F Robinson.   

Abstract

This study investigated the hypothesis that under certain conditions, superinfection of cats with feline immunodeficiency virus (FIV), may occur. One FIV isolate (T91) was used to inoculate three FIV and FeLV-free cats. Blood from an FIV-infected cat (N), which contained two variants and differed from T91 by at least 5% in nucleotide sequence in the env gene, was inoculated into a fourth cat. Both T91 and blood from N were inoculated simultaneously into a fifth cat. After 22 weeks, two of the three cats initially infected with T91 were challenged with blood from N. At 30 weeks following initial infection, peripheral blood mononuclear cells were obtained from all cats, DNA was extracted, and a segment of the env gene was PCR amplified, cloned and sequenced. Nucleotide sequence analysis of the cloned PCR product showed that virus strains used in initial infection were recovered from cats not challenged with a second variant. Challenge of cats with the blood of N following initial infection with T91 resulted in superinfection occurring in one cat and recombination occurring in the other. Furthermore, the use of blood as a source of challenge, in cats where superinfection and simultaneous infections were attempted, may have induced the appearance of variants which more closely resembled the most heterologous strain present in the infectious source.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7998833     DOI: 10.1007/BF01379130

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  33 in total

1.  In hot pursuit of an HIV vaccine.

Authors:  B J Spalding
Journal:  Biotechnology (N Y)       Date:  1992-01

2.  Effectiveness of AIDS vaccines.

Authors:  A B Sabin
Journal:  Science       Date:  1991-03-08       Impact factor: 47.728

3.  Rapid generation of sequence variation during primary HIV-1 infection.

Authors:  S Pang; Y Shlesinger; E S Daar; T Moudgil; D D Ho; I S Chen
Journal:  AIDS       Date:  1992-05       Impact factor: 4.177

Review 4.  Sequence variability in human immunodeficiency viruses: pattern and process in viral evolution.

Authors:  A J Brown
Journal:  AIDS       Date:  1991       Impact factor: 4.177

5.  HIV-1 isolates are rapidly evolving quasispecies: evidence for viral mixtures and preferred nucleotide substitutions.

Authors:  M Goodenow; T Huet; W Saurin; S Kwok; J Sninsky; S Wain-Hobson
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1989

6.  Vaccine protection against simian immunodeficiency virus infection.

Authors:  R C Desrosiers; M S Wyand; T Kodama; D J Ringler; L O Arthur; P K Sehgal; N L Letvin; N W King; M D Daniel
Journal:  Proc Natl Acad Sci U S A       Date:  1989-08       Impact factor: 11.205

7.  A formalin-inactivated whole SIV vaccine confers protection in macaques.

Authors:  M Murphey-Corb; L N Martin; B Davison-Fairburn; R C Montelaro; M Miller; M West; S Ohkawa; G B Baskin; J Y Zhang; S D Putney
Journal:  Science       Date:  1989-12-08       Impact factor: 47.728

8.  Consequences of human immunodeficiency virus type 1 superinfection of chronically infected cells.

Authors:  J H Kim; J D Mosca; M T Vahey; R J McLinden; D S Burke; R R Redfield
Journal:  AIDS Res Hum Retroviruses       Date:  1993-09       Impact factor: 2.205

9.  Feline immunodeficiency virus: quantification in peripheral blood mononuclear cells and isolation from plasma of infected cats.

Authors:  J Meers; W F Robinson; G M del Fierro; M A Scoones; M A Lawson
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Infection of cynomolgus monkeys with HIV-2 protects against pathogenic consequences of a subsequent simian immunodeficiency virus infection.

Authors:  P Putkonen; R Thorstensson; J Albert; K Hild; E Norrby; P Biberfeld; G Biberfeld
Journal:  AIDS       Date:  1990-08       Impact factor: 4.177

View more
  7 in total

1.  Size variation within the second hypervariable region of the surface envelope gene of the bovine lentivirus BIV in experimentally and naturally infected cattle.

Authors:  D L Suarez; C A Whetstone
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

2.  Quasispecies and naturally occurring superinfection in feline immunodeficiency virus infection.

Authors:  M T Kyaw-Tanner; W F Robinson
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

3.  Novel and dynamic evolution of equine infectious anemia virus genomic quasispecies associated with sequential disease cycles in an experimentally infected pony.

Authors:  C Leroux; C J Issel; R C Montelaro
Journal:  J Virol       Date:  1997-12       Impact factor: 5.103

4.  Kinetics of replication of a partially attenuated virus and of the challenge virus during a three-year intersubtype feline immunodeficiency virus superinfection experiment in cats.

Authors:  M Pistello; D Matteucci; G Cammarota; P Mazzetti; S Giannecchini; D Del Mauro; S Macchi; L Zaccaro; M Bendinelli
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

5.  Genetic and phylogenetic divergence of feline immunodeficiency virus in the puma (Puma concolor).

Authors:  M A Carpenter; E W Brown; M Culver; W E Johnson; J Pecon-Slattery; D Brousset; S J O'Brien
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

6.  Feline immunodeficiency virus (FIV) env recombinants are common in natural infections.

Authors:  Paweł M Bęczkowski; Joseph Hughes; Roman Biek; Annette Litster; Brian J Willett; Margaret J Hosie
Journal:  Retrovirology       Date:  2014-09-17       Impact factor: 4.602

7.  Decreased Sensitivity of the Serological Detection of Feline Immunodeficiency Virus Infection Potentially Due to Imported Genetic Variants.

Authors:  Julia Frankenfeld; Theres Meili; Marina L Meli; Barbara Riond; A Katrin Helfer-Hungerbuehler; Eva Bönzli; Benita Pineroli; Regina Hofmann-Lehmann
Journal:  Viruses       Date:  2019-07-31       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.